Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 125 versus NALLPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 125 versus NALLPEN.
AUGMENTIN '125' vs NALLPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation. Clavulanate is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamases, preventing hydrolysis of amoxicillin.
NALLPEN (naloxone) is a competitive opioid receptor antagonist that binds to mu, kappa, and delta opioid receptors, reversing the effects of opioid agonists including respiratory depression, sedation, and hypotension.
One AUGMENTIN '125' tablet (amoxicillin 125 mg, clavulanate 31.25 mg) orally every 8 hours for mild to moderate infections.
1 gram IV every 8 hours over 30 minutes.
None Documented
None Documented
Amoxicillin: 1.0-1.3 hours (prolonged in renal impairment; up to 7-20 hours in anuria). Clavulanate: 0.9-1.2 hours (increased in renal impairment).
Terminal elimination half-life is 2.0-3.0 hours; prolonged in renal impairment (up to 24 hours).
Amoxicillin: ~50-70% excreted unchanged in urine via glomerular filtration and tubular secretion; clavulanate: ~30-50% excreted unchanged in urine. Small amounts eliminated in bile and feces.
Primarily renal excretion (80-90% unchanged) with minor biliary/fecal elimination (5-10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic